| Name: | Emtricitabine Diastereomer |
| Catalogue No. | VL54004 |
| CAS No. | 143491-54-7 |
| Molecular Formula | C8H10N3O3FS |
| Molecular Weight | 247.25 |
| Status | In-stock |
| IUPAC Name | 4-amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one |
| Description | Emtricitabine Diastereomer (CAS No.143491-54-7) or 4-amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) in combination with other antiviral agents it shows activity against HIV. It is approved for the use in combination therapy. |
| References | "Sax, Paul E., et al. “Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide, for Initial Treatment of HIV-1 Infection (GS-US-380–1490): A Randomised, Double-Blind, Multicentre, Phase 3, Non-Inferiority Trial.” The Lancet, vol. 390, no. 10107, Nov. 2017, pp. 2073–82, https://doi.org/10.1016/s0140-6736(17)32340-1. Bang, Lynne M., and Lesley J. Scott. “Emtricitabine.” Drugs, vol. 63, no. 22, 2003, pp. 2413–24, https://do |
